In patients with pSS, the simultaneous presence of anti-SSA/Ro antibodies in serum and upregulated TRIM29 in saliva enabled 99.5% differentiation from non-pSS patients with pSS-like symptoms and signs, thereby providing a diagnostic accuracy that may exceed the currently available biomarkers for pSS. The gene discussed is TRIM29; the disease is peeling skin syndrome.